US20040122000A1
(en)
*
|
1981-01-07 |
2004-06-24 |
Vertex Pharmaceuticals Incorporated. |
Inhibitors of aspartyl protease
|
UA59384C2
(uk)
*
|
1996-12-20 |
2003-09-15 |
Пфайзер, Інк. |
Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
|
US6436989B1
(en)
*
|
1997-12-24 |
2002-08-20 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of aspartyl protease inhibitors
|
BR9911612A
(pt)
|
1998-06-02 |
2001-02-06 |
Osi Pharm Inc |
Composições de pirrolo[2,3d]pirimidina e seus usos
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
GB9815567D0
(en)
*
|
1998-07-18 |
1998-09-16 |
Glaxo Group Ltd |
Antiviral compound
|
AU6329599A
(en)
*
|
1998-09-28 |
2000-04-17 |
Glaxo Group Limited |
Antiviral combinations comprising (s)-2-ethyl -7-fluoro -3-oxo-3, 4-dihydro -2h-quinoxaline -1-carboxylic acid isopropyl ester
|
GB9914821D0
(en)
*
|
1999-06-24 |
1999-08-25 |
Glaxo Group Ltd |
Compounds
|
US7160890B2
(en)
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6680324B2
(en)
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
BR0207862A
(pt)
|
2001-02-14 |
2004-06-22 |
Tibotec Pharm Ltd |
Inibidores de protease de hiv 2-(amino-substituìda)-benzotiazol-sulfonamida de amplo espectro
|
CZ303139B6
(cs)
|
2001-04-09 |
2012-04-25 |
Tibotec Pharmaceuticals Ltd. |
2-(substituovaný amino)-benzoxazolsulfonamidový derivát, farmaceutická kompozice s jeho obsahem a zpusob in vitro inhibice retrovirové replikace
|
AR035970A1
(es)
|
2001-05-11 |
2004-07-28 |
Tibotec Pharm Ltd |
2-amino-benzoxazol sulfonamidas inhibidoras de amplio espectro de la hiv proteasa, composicion farmaceutica, metodo "in vitro" para inhibir la replicacion retroviral, y utilizacion de estos compuestos en la manufactura de medicamentos
|
US7576084B2
(en)
*
|
2001-10-12 |
2009-08-18 |
Choongwae Pharma Corporation |
Reverse-turn mimetics and method relating thereto
|
JP2005529062A
(ja)
|
2001-11-30 |
2005-09-29 |
オーエスアイ・ファーマスーティカルズ・インコーポレーテッド |
アデノシンa1及びa3受容体に特異的な化合物とその使用
|
TWI286476B
(en)
*
|
2001-12-12 |
2007-09-11 |
Tibotec Pharm Ltd |
Combination of cytochrome P450 dependent protease inhibitors
|
CN101973998A
(zh)
|
2001-12-20 |
2011-02-16 |
Osi药物公司 |
吡咯并嘧啶A2b选择性拮抗剂化合物
|
EP1465631B1
(en)
|
2001-12-20 |
2010-02-24 |
OSI Pharmaceuticals, Inc. |
Pyrimidine a2b selective antagonist compounds, their synthesis and use
|
AU2002361235B2
(en)
|
2001-12-21 |
2008-07-24 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum heterocyclic substituted phenyl containing sulfonamide HIV protease inhibitors
|
US7157489B2
(en)
*
|
2002-03-12 |
2007-01-02 |
The Board Of Trustees Of The University Of Illinois |
HIV protease inhibitors
|
MY142238A
(en)
|
2002-03-12 |
2010-11-15 |
Tibotec Pharm Ltd |
Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
|
BR0309557A
(pt)
*
|
2002-04-26 |
2005-03-01 |
Gilead Sciences Inc |
Inibidores da transcriptase reversa não nucleosìdeos
|
SI1517899T1
(sl)
|
2002-05-17 |
2008-02-29 |
Tibotec Pharm Ltd |
Substituirani benzoksazol sulfonamidi sirokega spektra, ki so HIV proteazni inhibitorji
|
WO2004016619A1
(en)
|
2002-08-14 |
2004-02-26 |
Tibotec Pharmaceuticals Ltd. |
Broadspectrum substituted oxindole sulfonamide hiv protease inhibitors
|
DE10303974A1
(de)
|
2003-01-31 |
2004-08-05 |
Abbott Gmbh & Co. Kg |
Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
|
CA2425031A1
(en)
*
|
2003-04-01 |
2004-10-01 |
Smithkline Beecham Corporation |
Pharmaceutical compositions
|
EA014685B1
(ru)
|
2003-04-25 |
2010-12-30 |
Джилид Сайэнс, Инк. |
Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
|
US7470724B2
(en)
|
2003-04-25 |
2008-12-30 |
Gilead Sciences, Inc. |
Phosphonate compounds having immuno-modulatory activity
|
US7452901B2
(en)
|
2003-04-25 |
2008-11-18 |
Gilead Sciences, Inc. |
Anti-cancer phosphonate analogs
|
WO2004096285A2
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Anti-infective phosphonate conjugates
|
US7407965B2
(en)
|
2003-04-25 |
2008-08-05 |
Gilead Sciences, Inc. |
Phosphonate analogs for treating metabolic diseases
|
US7427636B2
(en)
|
2003-04-25 |
2008-09-23 |
Gilead Sciences, Inc. |
Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
|
WO2005002626A2
(en)
|
2003-04-25 |
2005-01-13 |
Gilead Sciences, Inc. |
Therapeutic phosphonate compounds
|
US7432261B2
(en)
|
2003-04-25 |
2008-10-07 |
Gilead Sciences, Inc. |
Anti-inflammatory phosphonate compounds
|
AU2004233897A1
(en)
|
2003-04-25 |
2004-11-11 |
Gilead Sciences, Inc. |
Kinase inhibitor phosphonate conjugates
|
EP2292590A3
(en)
*
|
2003-07-09 |
2012-05-02 |
Paratek Pharmaceuticals, Inc. |
Prodrugs of 9-aminomethyl tetracycline compounds
|
EA201001081A1
(ru)
|
2003-07-09 |
2011-02-28 |
Пэрэтек Фамэсьютикэлс, Инк. |
Соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта
|
US20050119163A1
(en)
|
2003-09-18 |
2005-06-02 |
The Government Of The United States Of America, As Represented By The Secretary, |
SH2 domain binding inhibitors
|
US7432273B2
(en)
|
2003-10-24 |
2008-10-07 |
Gilead Sciences, Inc. |
Phosphonate analogs of antimetabolites
|
US7427624B2
(en)
|
2003-10-24 |
2008-09-23 |
Gilead Sciences, Inc. |
Purine nucleoside phosphorylase inhibitory phosphonate compounds
|
US7834043B2
(en)
*
|
2003-12-11 |
2010-11-16 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
US20050131042A1
(en)
*
|
2003-12-11 |
2005-06-16 |
Flentge Charles A. |
HIV protease inhibiting compounds
|
US8193227B2
(en)
|
2003-12-11 |
2012-06-05 |
Abbott Laboratories |
HIV protease inhibiting compounds
|
MY148233A
(en)
*
|
2003-12-15 |
2013-03-29 |
Merck Sharp & Dohme |
Heterocyclic aspartyl protease inhibitors
|
CA2549869C
(en)
|
2003-12-18 |
2015-05-05 |
Janssen Pharmaceutica N.V. |
Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
|
NZ547907A
(en)
|
2003-12-22 |
2010-07-30 |
Gilead Sciences Inc |
4'-Substituted carbovir-and abacavir-derivatives as well as related compounds with HIV and HCV antiviral activity
|
KR101229431B1
(ko)
|
2004-07-06 |
2013-02-04 |
아보트 러보러터리즈 |
Hiv 프로테아제 억제제의 프로드럭
|
UA88313C2
(ru)
|
2004-07-27 |
2009-10-12 |
Гилиад Сайенсиз, Инк. |
Фосфонатные аналоги соединений ингибиторов вич
|
EP2165709B1
(en)
*
|
2004-08-02 |
2016-03-16 |
Ambrilia Biopharma Inc. |
Pharmaceutical compositions comprising a lysine based compound and an HIV antiviral or antiretroviral agent
|
US7388008B2
(en)
*
|
2004-08-02 |
2008-06-17 |
Ambrilia Biopharma Inc. |
Lysine based compounds
|
US20070292478A1
(en)
|
2004-08-30 |
2007-12-20 |
Popowski Youri |
Medical Implant Provided with Inhibitors of Atp Synthesis
|
AU2005311251A1
(en)
|
2004-12-01 |
2006-06-08 |
Devgen Nv |
5-carboxamido substituted thiazole derivatives that interact with ion channels, in particular with ion channels from the Kv family
|
NI200700147A
(es)
|
2004-12-08 |
2019-05-10 |
Janssen Pharmaceutica Nv |
Derivados de quinazolina inhibidores de cinasas dirigidos a multip
|
DK1941798T3
(da)
|
2004-12-17 |
2012-08-27 |
Devgen Nv |
Nematicide præparater
|
BRPI0606318B8
(pt)
*
|
2005-01-19 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, composição, e, uso de um composto
|
US20080194554A1
(en)
*
|
2005-03-11 |
2008-08-14 |
Mclean Ed W |
Hiv Protease Inhibitors
|
AR053845A1
(es)
|
2005-04-15 |
2007-05-23 |
Tibotec Pharm Ltd |
5-tiazolilmetil[(1s,2r)-3-[[(2-amino-6-benzoxazolil)sulfonil)](2-metilpropil)amino]-2-hidroxi-1-(fenilmetil)propil]carbamato como mejorador de farmacos metabolizados por el citocromo p450
|
ES2539527T3
(es)
|
2005-04-27 |
2015-07-01 |
Taimed Biologics, Inc. |
Método para mejorar la farmacocinética de los inhibidores de las proteasas y de los precursores de los inhibidores de las proteasas
|
US8003627B2
(en)
|
2005-10-21 |
2011-08-23 |
Universiteit Antwerpen |
Urokinase inhibitors
|
AR058238A1
(es)
|
2005-11-28 |
2008-01-23 |
Tibotec Pharm Ltd |
Compuestos y derivados de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
|
AR057182A1
(es)
|
2005-11-28 |
2007-11-21 |
Tibotec Pharm Ltd |
Compuestos de aminofenilsulfonamida sustituida como inhibidores de proteasa del vih
|
PT1954718E
(pt)
|
2005-11-30 |
2014-12-16 |
Abbvie Inc |
Anticorpos anti-globulómeros aβ, suas porções de ligação ao antigénio, correspondentes hibridomas, ácidos nucleicos, vectores, células hospedeiras, métodos de produção dos ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos para uso dos ditos anticorpos
|
DK1976877T4
(en)
|
2005-11-30 |
2017-01-16 |
Abbvie Inc |
Monoclonal antibodies to amyloid beta protein and uses thereof
|
CA2632095A1
(en)
*
|
2005-11-30 |
2007-06-07 |
Ambrilia Biopharma Inc. |
Lysine-based prodrugs of aspartyl protease inhibitors and processes for their preparation
|
US20100004206A1
(en)
*
|
2005-12-27 |
2010-01-07 |
Makoto Komatsu |
Water-soluble benzoazepine compound and its pharmaceutical composition
|
AU2007274284B2
(en)
|
2006-07-13 |
2012-04-26 |
Janssen Pharmaceutica N.V. |
Mtki quinazoline derivatives
|
WO2008028688A2
(en)
|
2006-09-08 |
2008-03-13 |
Bayer Schering Pharma Aktiengesellschaft |
Compounds and methods for 18f labeled agents
|
ES2628730T3
(es)
*
|
2006-09-21 |
2017-08-03 |
Taimed Biologics, Inc. |
Inhibidores de proteasa
|
US8455626B2
(en)
|
2006-11-30 |
2013-06-04 |
Abbott Laboratories |
Aβ conformer selective anti-aβ globulomer monoclonal antibodies
|
WO2008104386A2
(en)
|
2007-02-27 |
2008-09-04 |
Abbott Gmbh & Co. Kg |
Method for the treatment of amyloidoses
|
CN101631568B
(zh)
|
2007-03-12 |
2012-08-22 |
尼克塔治疗公司 |
低聚物-蛋白酶抑制剂偶联物
|
ES2562218T3
(es)
|
2007-07-27 |
2016-03-03 |
Janssen Pharmaceutica, N.V. |
Pirrolopirimidinas útiles para el tratamiento de enfermedades proliferativas
|
EP2053033A1
(en)
|
2007-10-26 |
2009-04-29 |
Bayer Schering Pharma AG |
Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
|
EP2100900A1
(en)
|
2008-03-07 |
2009-09-16 |
Universitätsspital Basel |
Bombesin analog peptide antagonist conjugates
|
WO2009112439A1
(en)
|
2008-03-10 |
2009-09-17 |
Janssen Pharmaceutica Nv |
4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
|
WO2009114151A1
(en)
*
|
2008-03-12 |
2009-09-17 |
Nektar Therapeutics |
Oligomer-amino acid and olgomer-atazanavir conjugates
|
EP2116236A1
(en)
|
2008-04-21 |
2009-11-11 |
Université de Mons-Hainaut |
Bisbenzamidine derivatives for use as antioxidant
|
EA018308B1
(ru)
|
2008-07-08 |
2013-07-30 |
Джилид Сайэнс, Инк. |
Соли соединений ингибиторов вич
|
EA021377B9
(ru)
|
2008-12-09 |
2015-09-30 |
Джилид Сайэнс, Инк. |
Модуляторы толл-подобных рецепторов
|
WO2010134045A1
(en)
*
|
2009-05-20 |
2010-11-25 |
Ranbaxy Laboratories Limited |
Amorphous fosamprenavir calcium
|
EP2440249A2
(en)
|
2009-06-12 |
2012-04-18 |
Nektar Therapeutics |
Covalent conjugates comprising a protease inhibitor, a water-soluble, non-peptidic oligomer and a lipophilic moiety
|
CA2774483C
(en)
|
2009-09-16 |
2014-11-18 |
Ranbaxy Laboratories Limited |
Process for the preparation of fosamprenavir calcium
|
WO2011061590A1
(en)
|
2009-11-17 |
2011-05-26 |
Hetero Research Foundation |
Novel carboxamide derivatives as hiv inhibitors
|
WO2011061295A1
(en)
|
2009-11-19 |
2011-05-26 |
Blue Medical Devices Bv |
Narrow profile composition-releasing expandable medical balloon catheter
|
WO2011085130A1
(en)
|
2010-01-07 |
2011-07-14 |
Pliva Hrvatska D.O.O. |
Solid state forms of fosamprenavir calcium salt and process for preparation thereof
|
KR20170078868A
(ko)
|
2010-01-27 |
2017-07-07 |
비이브 헬쓰케어 컴퍼니 |
항바이러스 치료
|
US20110223131A1
(en)
|
2010-02-24 |
2011-09-15 |
Gilead Sciences, Inc. |
Antiviral compounds
|
US20110224443A1
(en)
*
|
2010-03-15 |
2011-09-15 |
Venkata Naga Brahmeshwara Rao Mandava |
Preparation of fosamprenavir calcium
|
WO2011114212A1
(en)
|
2010-03-19 |
2011-09-22 |
Lupin Limited |
Ammonium, calcium and tris salts of fosamprenavir
|
MX360403B
(es)
|
2010-04-15 |
2018-10-31 |
Abbvie Inc |
Proteinas de union a amiloide beta.
|
WO2011141515A1
(en)
|
2010-05-14 |
2011-11-17 |
Bayer Pharma Aktiengesellschaft |
Diagnostic agents for amyloid beta imaging
|
WO2011158259A1
(en)
|
2010-06-18 |
2011-12-22 |
Matrix Laboratories Ltd |
Novel process for the preparation of (3s)-tetrahydrofuran-3-yl (is, 2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-(phosphonooxy) propylcarbamate and its pharmaceutically acceptable salts thereof
|
US8785648B1
(en)
|
2010-08-10 |
2014-07-22 |
The Regents Of The University Of California |
PKC-epsilon inhibitors
|
EP2603524A1
(en)
|
2010-08-14 |
2013-06-19 |
AbbVie Inc. |
Amyloid-beta binding proteins
|
EP2614055A2
(en)
|
2010-09-10 |
2013-07-17 |
Lupin Limited |
Process for preparation of substantially pure fosamprenavir calcium and its intermediates
|
GB201019043D0
(en)
|
2010-11-10 |
2010-12-22 |
Protea Biopharma N V |
Use of 2',5'-oligoadenylate derivative compounds
|
WO2012085625A1
(en)
|
2010-12-21 |
2012-06-28 |
Lupin Limited |
Process for the preparation of fosamprenavir calcium and intermediate used in its preparation
|
US8993786B2
(en)
*
|
2011-02-10 |
2015-03-31 |
Mylan Laboratories Ltd. |
Crystalline fosamprenavir calcium and process for the preparation thereof
|
KR102395085B1
(ko)
|
2011-06-21 |
2022-05-09 |
알닐람 파마슈티칼스 인코포레이티드 |
안지오포이에틴-유사 3(ANGPTL3) iRNA 조성물 및 그 사용 방법
|
EP3597750B1
(en)
|
2011-06-23 |
2022-05-04 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
US9309213B2
(en)
|
2011-07-11 |
2016-04-12 |
Purdue Research Foundation |
C-3 substituted bicyclooctane based HIV protease inhibitors
|
WO2013011485A1
(en)
|
2011-07-20 |
2013-01-24 |
Ranbaxy Laboratories Limited |
Process for the preparation of sulfonamides useful as retroviral protease inhibitors
|
IN2012DE00082A
(US06559137-20030506-C00158.png)
|
2012-01-10 |
2015-05-01 |
Council Scient Ind Res |
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2700396A3
(en)
|
2012-06-20 |
2015-04-29 |
Sylphar Nv |
Strip for the delivery of oral care compositions
|
WO2014059034A2
(en)
|
2012-10-09 |
2014-04-17 |
President And Fellows Of Harvard College |
Nad biosynthesis and precursors for the treatment and prevention of cancer and proliferation
|
US9227990B2
(en)
|
2012-10-29 |
2016-01-05 |
Cipla Limited |
Antiviral phosphonate analogues and process for preparation thereof
|
RS56783B9
(sr)
|
2012-12-05 |
2021-12-31 |
Alnylam Pharmaceuticals Inc |
Sastavi pcsk9 irnk i postupci njihovih primena
|
CA2904654C
(en)
|
2013-03-14 |
2023-12-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
HUE038146T2
(hu)
|
2013-05-22 |
2018-09-28 |
Alnylam Pharmaceuticals Inc |
Serpina1 IRNS készítmények és eljárások alkalmazásukra
|
BR112015029276B1
(pt)
|
2013-05-22 |
2022-07-12 |
Alnylam Pharmaceuticals, Inc |
Agente de irna fita dupla capaz de inibir a expressão de tmprss6, composição farmacêutica e uso dos mesmos
|
SG11201604692UA
(en)
|
2013-12-12 |
2016-07-28 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
CN106103718B
(zh)
|
2014-02-11 |
2021-04-02 |
阿尔尼拉姆医药品有限公司 |
己酮糖激酶(KHK)iRNA组合物及其使用方法
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療serpinc1相關疾患之方法和組成物
|
MX2016015126A
(es)
|
2014-05-22 |
2017-02-23 |
Alnylam Pharmaceuticals Inc |
Composiciones de angiotensinogeno (agt) arni y metodos de uso de las mismas.
|
WO2016003450A1
(en)
|
2014-07-01 |
2016-01-07 |
The Regents Of The University Of California |
Pkc-epsilon inhibitors
|
WO2016001907A1
(en)
|
2014-07-02 |
2016-01-07 |
Prendergast Patrick T |
Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
|
TWI806081B
(zh)
|
2014-07-11 |
2023-06-21 |
美商基利科學股份有限公司 |
用於治療HIV之toll樣受體調節劑
|
WO2016040589A1
(en)
|
2014-09-12 |
2016-03-17 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting complement component c5 and methods of use thereof
|
EP3207138B1
(en)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
|
EP3212196A4
(en)
|
2014-10-29 |
2018-07-11 |
Wisconsin Alumni Research Foundation |
Boronic acid inhibitors of hiv protease
|
EP3212794B1
(en)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
WO2016083490A1
(en)
|
2014-11-27 |
2016-06-02 |
Remynd Nv |
Compounds for the treatment of amyloid-associated diseases
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
TWI723986B
(zh)
|
2015-04-13 |
2021-04-11 |
美商阿尼拉製藥公司 |
類血管生成素3(ANGPTL3)iRNA組成物及其用途方法
|
AU2016255853B2
(en)
|
2015-04-28 |
2021-08-05 |
Newsouth Innovations Pty Limited |
Targeting NAD+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies and inactivity
|
CN108271386B
(zh)
|
2015-05-06 |
2022-07-15 |
阿尔尼拉姆医药品有限公司 |
因子XII(哈格曼因子)(F12)、激肽释放酶B、血浆(夫列契因子)1(KLKB1)和激肽原1(KNG1)iRNA组合物及其使用方法
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
EP3349757A1
(en)
|
2015-09-15 |
2018-07-25 |
Gilead Sciences, Inc. |
Modulators of toll-like recptors for the treatment of hiv
|
RU2754188C2
(ru)
|
2015-12-07 |
2021-08-30 |
Джензим Корпорейшн |
Способы и композиции для лечения ассоциированного с serpinc1 расстройства
|
JP2018536689A
(ja)
|
2015-12-10 |
2018-12-13 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
ステロール調節エレメント結合タンパク質(SREBP)シャペロン(SCAP)iRNA組成物およびその使用方法
|
JP2019518028A
(ja)
|
2016-06-10 |
2019-06-27 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
補体成分C5iRNA組成物及び発作性夜間血色素尿症(PNH)を処置するためのその使用方法
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
SG10201913552UA
(en)
|
2016-12-16 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
EP3621963B1
(en)
|
2017-05-11 |
2024-01-24 |
Remynd N.V. |
Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders
|
KR20200031658A
(ko)
|
2017-07-21 |
2020-03-24 |
비이브 헬쓰케어 컴퍼니 |
Hib 감염 및 aids를 치료하기 위한 요법
|
PL3661937T3
(pl)
|
2017-08-01 |
2021-12-20 |
Gilead Sciences, Inc. |
Formy krystaliczne ((s)-((((2r,5r)-5-(6-amino-9h-puryn-9-ylo)-4-fluoro-2,5-dihydrofuran-2-ylo)oksy)metylo)(fenoksy)fosforylo)-l-alaninianu etylu (gs-9131) do leczenia zakażeń wirusowych
|
EP3704252A1
(en)
|
2017-11-01 |
2020-09-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
MX2021001056A
(es)
|
2018-08-13 |
2021-04-12 |
Alnylam Pharmaceuticals Inc |
Composiciones de agente de acido ribonucleico bicatenario (arnbc) de virus de la hepatitis b (vhb) y metodos de uso de las mismas.
|
MX2021008628A
(es)
|
2019-01-16 |
2021-11-17 |
Genzyme Corp |
Composiciones de arni para serpinc1 y metodos de uso de las mismas.
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
AU2021225333A1
(en)
|
2020-02-24 |
2022-08-11 |
Katholieke Universiteit Leuven |
Pyrrolopyridine and imidazopyridine antiviral compounds
|
US20230218644A1
(en)
|
2020-04-16 |
2023-07-13 |
Som Innovation Biotech, S.A. |
Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
|
US12083099B2
(en)
|
2020-10-28 |
2024-09-10 |
Accencio LLC |
Methods of treating symptoms of coronavirus infection with viral protease inhibitors
|
AU2021405511A1
(en)
|
2020-12-22 |
2023-06-22 |
Luxembourg Institute Of Health (Lih) |
Conolidine analogues as selective ackr3 modulators for the treatment of cancer and cardiovascular diseases
|
EP4301369A1
(en)
|
2021-03-04 |
2024-01-10 |
Universiteit Antwerpen |
Quinazolin-4-one and thieno[2,3-d]pyrimidin-4-one inhibitors of erbb4 (her4) for use in the treatment of cancer
|
US20240238460A1
(en)
|
2021-05-31 |
2024-07-18 |
Telix Pharmaceuticals (Innovations) Pty Ltd |
Improved prostate-specific membrane antigen targeting radiopharmaceuticals and uses thereof
|
WO2023021132A1
(en)
|
2021-08-18 |
2023-02-23 |
Katholieke Universiteit Leuven |
6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
|
WO2023046900A1
(en)
|
2021-09-23 |
2023-03-30 |
Katholieke Universiteit Leuven |
Ribonucleoside analogues against -sars-cov-2
|
WO2023241799A1
(en)
|
2022-06-15 |
2023-12-21 |
Université Libre de Bruxelles |
Flavanols for use in the treatment of retroviral infections
|
WO2024062043A1
(en)
|
2022-09-21 |
2024-03-28 |
Universiteit Antwerpen |
Substituted phenothiazines as ferroptosis inhibitors
|
WO2024175804A1
(en)
|
2023-02-24 |
2024-08-29 |
Katholieke Universiteit Leuven |
Nuclear transport modulators
|